Helix Acqsn II SEC Filings

BridgeBio Pharma entities disclosed ownership of 13,878,554 shares of BridgeBio Oncology Therapeutics, Inc. following the closing of a business combination on August 11, 2025. The shares consist of 13,805,126 common shares and options exercisable into 73,428 shares, representing approximately 17.5% of the 79,196,710 shares outstanding after the closing. The acquisition resulted from the merger between Helix Acquisition Corp. II and TheRas, Inc. under the Business Combination Agreement. Two BridgeBio directors, Neil Kumar and Frank P. McCormick, were appointed to the Issuer's board. The Reporting Persons state the shares were acquired for investment purposes and are subject to a one-year lock-up and registration rights.

Form 3 filing by Tipirneni Praveen P. reports initial beneficial ownership in BridgeBio Oncology Therapeutics, Inc. (Ticker: BBOT). The filing, covering an event dated 08/11/2025, identifies the reporting person as a director and discloses two stock option awards exercisable for common stock. One option covers 81,069 shares with an exercise price of $5.18 and an exercisable date shown as 12/25/2034. The second option covers 4,855 shares with an exercise price of $7.88 and an exercisable date shown as 04/02/2035. The filing states each option vests in 1/48th monthly installments starting November 11, 2024 (first option) and April 4, 2025 (second option), subject to continuous service. The form is signed by an attorney-in-fact on 08/18/2025.

Frank McCormick, a director of BridgeBio Oncology Therapeutics (BBOT), reported beneficial ownership consisting of two stock option awards. One option covers 141,870 shares exercisable in 2034 at $4.17 per share and a second option covers 8,497 shares exercisable in 2035 at $7.88 per share. Both awards vest monthly in equal installments as described in the filing. The Form 3 was submitted by one reporting person and includes a power of attorney.

BridgeBio Pharma LLC and its parent BridgeBio Pharma, Inc. reported an initial Form 3 disclosing 13,805,126 shares of common stock of BridgeBio Oncology Therapeutics, Inc. (BBOT) held indirectly. The filing shows two fully vested stock options covering 63,934 and 9,494 shares with exercise prices of $3.83 and $1.02, respectively. Voting and investment power is exercised by the parent, and the filers disclaim individual beneficial ownership except for any pecuniary interest.

Ben Yong filed an initial Form 3 reporting his beneficial ownership in BridgeBio Oncology Therapeutics, Inc. (BBOT). The filing shows two stock options exercisable for common stock: 443,298 shares at an exercise price of $4.17 (exercisable 09/24/2034) and 26,551 shares at $7.88 (exercisable 04/02/2035). Vesting terms are stated: 25% of the larger option vests on September 3, 2025, with the remainder monthly over 36 months; the smaller option vests monthly in 48 equal installments beginning April 4, 2025. The form lists his role as Chief Medical & Development Officer and is signed by an attorney-in-fact on his behalf.

Wallace Eli M. filed an initial Form 3 reporting his beneficial ownership in BridgeBio Oncology Therapeutics, Inc. (Ticker: BBOT). The filing shows two stock options: one for 620,618 shares of common stock exercisable beginning 07/22/2034 at an exercise price of $4.17, and one for 37,172 shares exercisable beginning 04/02/2035 at $7.88. The options vest monthly in 1/48th installments beginning May 1, 2024 and April 4, 2025 respectively, subject to continued service. The Form 3 indicates Wallace is both Chief Executive Officer and a Director. The filing was signed by an attorney-in-fact on 08/18/2025 and includes a Power of Attorney exhibit.